Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Habib Yaribeygi, Mina Maleki, Tannaz Jamialahamdi, Seyed Adel Moallem, Amirhossein Sahebkar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund 2023-04-01
Edice:	EXCLI Journal : Experimental and Clinical Sciences
Témata:	diabetes mellitus sodium-glucose cotransporter-2 inhibitors liver non-alcoholic fatty liver disorders fibrosis hepatocellular carcinoma cirrhosis
On-line přístup:	https://www.excli.de/index.php/excli/article/view/6022
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!